Safety, Tolerability, and Efficacy of MatriPlax in Subjects With Acute Respiratory Distress Syndrome

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

May 31, 2027

Conditions

Acute Respiratory Distress Syndrome

Interventions

DRUG

MatriPlax

MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4

Trial Locations (1)

Taipei Medical University Hospital, Taipei

All Listed Sponsors

lead

BioSpring Medical Co., Ltd

INDUSTRY

NCT05886985 - Safety, Tolerability, and Efficacy of MatriPlax in Subjects With Acute Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter